9th Nov 2020 17:28
4d Pharma PLC - Leeds-based pharmaceutical company - Reports positive clinical data from two clinical trials of lead immuno-oncology single strain live biotherapeutic candidate MRx051. An ongoing two-part phase 1 study is taking place in treatment-naive subjects undergoing surgical resection of solid tumours. This study finds relative increases in cytotoxic cells, CD8+ T cells and other immune subsets associated with anti-tumour activity. Analysis finds significant expression changes in 98 genes as a result of treatment with MRx0518 monotherapy generally well-tolerated.
Also ongoing is its part A phase 1/2 clinical trial evaluating the safety and preliminary efficacy of MRx0518 plus pembrolizumab in heavily pre-treated metastatic patients with solid tumours refractory to immune checkpoint inhibitors. In 5 of the 12 patients studied MRx0518 in combination with pembrolizumab provides clinical benefit and the combination is also generally well-tolerated. Furthermore, additional tumour type cohorts will be enrolled on its part B phase 1/2 clinical trial of MRx0518 in combination with pembrolizumab.
Current stock price: 110.50 pence; down 7.1% on Monday
Year-to-date change: up 11%
By Anna Farley; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
DDDD.L